OpinionPublished 9 October 2026The N2 dilemma in stage III NSCLC: toward a quantitative framework for trial designLuca Bertolaccini · Monica Casiraghi · Antonio Mazzella · Giorgio Lo Iacono · Lorenzo SpaggiariFrontiers in Oncologydoi 10.3389/fonc.2026.1866606